Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03136484 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 788
- Enrollment target
NCT03136484 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 788 participants.
The verdict
NCT03136484, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 788 participants
- Enrollment target
Study Summary
This trial is conducted in Africa, Asia, Europe, North and South America. The aim of the trial is to compare the effect of once-weekly (OW) dosing of subcutaneous semaglutide (1.0 mg) versus once-daily dosing of oral canagliflozin (300 mg) on glycaemic control in subjects with type 2 diabetes (T2D) on a background treatment of metformin
Interventions
- DRUG Semaglutide
- DRUG Placebo (semaglutide)
- DRUG Canagliflozin
- DRUG Placebo (canagliflozin)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 788 participants |
| Start Date | 2017-03-15 |
| Est. Completion | 2018-11-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03136484
The ClinicalTrials.gov registry entry for NCT03136484 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 788 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Semaglutide is the first listed.
NCT03136484 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03136484 about?
NCT03136484 is a clinical study titled "Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes". This trial is conducted in Africa, Asia, Europe, North and South America. The aim of the trial is to compare the effect of once-weekly (OW) dosing of subcutaneous semaglutide (1.0 mg) versus once-daily dosing of oral canagliflozin (300 mg) on glycaemic control in subjects with type 2 diabetes (T2D) ...
What is the current status of trial NCT03136484?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 788 participants. The study started on 2017-03-15. Estimated completion is 2018-11-16.
What interventions are being tested in trial NCT03136484?
The interventions under investigation include: Semaglutide (DRUG), Placebo (semaglutide) (DRUG), Canagliflozin (DRUG), Placebo (canagliflozin) (DRUG).
Who is sponsoring clinical trial NCT03136484?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.